Prelude Therapeutics Inc (PRLD) Form 10-Q — May 12, 2026
Prelude Therapeutics Inc reported a net loss of $10.4 million for the quarter ended March 31, 2026, a significant improvement from the $32.1 million loss in the same period last year. The company recognized $4.6 million in revenue from its Exclusive Option Agreement with Incyte, which was entered into in November 2025. Research and development expenses decreased from $28.8 million in the first quarter of 2025 to $13.6 million in the first quarter of 2026, primarily due to the pause in the SMARCA2 degrader program. General and administrative expenses also decreased from $5.8 million to $5.2 million, driven by a reduction in non-cash stock-based compensation expense.
Key figures
- Eps Beat
- 0
- Revenue
- 4580
- Guidance
- The Company believes these funds will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10-Q.
- Total Debt
- 59459
- Debt Amount
- 0
- Revenue Yoy
- 4580
- Total Assets
- 119642
- Cash Position
- 84800
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 79645307
- Restricted Cash
- 3235
- Deferred Revenue
- 30952
- Marketable Securities
- 59798
- Cash And Cash Equivalents
- 21756
Price after filing
Close on the filing date to close N calendar days later (from $4.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.